# Study of INKmune in Patients With mCRPC (CaRe Prostate)

> **NCT06056791** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inmune Bio, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Cancer
- Metastatic Castration-resistant Prostate Cancer
- mCRPC

## Interventions

- **BIOLOGICAL:** INKmune

## Key facts

- **NCT ID:** NCT06056791
- **Lead sponsor:** Inmune Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-30
- **Primary completion:** 2025-09-10
- **Final completion:** 2025-09-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06056791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06056791, "Study of INKmune in Patients With mCRPC (CaRe Prostate)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06056791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*